Nano-X Imaging Ltd. — Form 6-K Summary
Filing date: May 22, 2023. Reporting context: Form 6-K for May 2023, including a press release as Exhibit 99.1. The filing references financial information as of March 31, 2023 and corrects a prior-period cash-flow classification for the quarter ended March 31, 2022.
Business Context and Financial Metrics
- The filing concerns Nano-X Imaging Ltd., an Israel-based medical imaging technology company developing the Nanox.ARC system.
- The provided filing text does not include the press release’s detailed revenue, loss, cash-flow, margin, debt, liquidity, or other operating metrics.
- The company disclosed that it uses non-GAAP financial measures in the press release. These measures exclude, among other items, legal and related expenses; the filing does not provide the full reconciliation or quantified non-GAAP results.
Material Changes and Accounting Correction
- The company corrected the classification of approximately $4.233 million previously reported as proceeds from the sale of marketable securities in financing activities for the quarter ended March 31, 2022.
- The corrected amounts are approximately $3.705 million classified as proceeds from maturity of marketable securities in investing activities and $0.528 million classified as amortization of premium, discount, and accrued interest on marketable securities in operating activities.
- The correction had no impact on total cash as of March 31, 2022. The company stated that the error relates to previously disclosed material weaknesses in internal control over financial reporting.
- The company is implementing a remediation plan, including enhancing and supplementing its finance team and internal-control resources.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide clear financial guidance or quantified operating outlook.
- On April 28, 2023, the company signed a term sheet with plaintiffs in the McLaughlin and consolidated White securities class actions. The proposed settlement remains subject to a formal agreement and court approval.
- As of March 31, 2023, the company had accrued $8 million for future settlement expenses related to the two class actions.
- The SEC is investigating potential federal securities-law violations, including matters relating to Nanox.ARC prototype development costs and estimated scaled assembly costs. The company is cooperating, but stated that the timing, outcome, and potential losses cannot be predicted or estimated. An adverse outcome could materially affect operations and financial condition.
- On May 1, 2023, the company received a claim alleging breach of a consulting agreement involving Nanox Gibraltar PLC. The claimant seeks approximately $1.26 million in unpaid consulting fees and approximately $25 million relating to alleged entitlement to Gibraltar Entity securities. The company believes the claims lack merit and intends to defend itself.
Investor Verification Items
- Verify the complete Exhibit 99.1 press release for current revenue, losses, cash flow, liquidity, cash balance, debt, margins, and non-GAAP reconciliations.
- Confirm the final terms, court approval, funding, and accounting treatment of the proposed securities-class-action settlement.
- Monitor developments in the SEC investigation and assess potential financial, regulatory, and disclosure consequences.
- Review the company’s remediation of material weaknesses and subsequent internal-control disclosures.
- Assess the merits and potential exposure associated with the May 1, 2023 consulting-related claim.